Preparation and characterization of poly lactide-co-glycolide nanoparticles of SN-38

PDA Journal of Pharmaceutical Science and Technology

Volumn 63, Issue 6, 2009, Pages 512-520

  Ebrahimnejad, P ^a,b   Dinarvand, Rassoul ^a,c   Sajadi, S A ^b   Atyabi, F ^a,c   Ramezani, F ^a   Jaafari, M R ^d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Irinotecan; Nanoparticles; Nanotechnology; Poly lactide co glycolide; Polyvinyl alcohol; SN 38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; IRINOTECAN; NANOPARTICLE; POLYGLACTIN; POLYVINYL ALCOHOL;

AQUEOUS SOLUTION; ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; EMULSION; HYDROPHOBICITY; IN VITRO STUDY; NANOENCAPSULATION; PARTICLE SIZE; PHYSICAL CHEMISTRY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG STABILITY; DRUG STORAGE; HYDROPHOBICITY; LACTIC ACID; NANOPARTICLES; NANOTECHNOLOGY; PARTICLE SIZE; POLYGLYCOLIC ACID; POLYVINYL ALCOHOL; SOLUBILITY; SOLVENTS; SURFACE-ACTIVE AGENTS;

EID: 70350710478     PISSN: 10797440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Kunii, R.; Onishi, H.; Ueki, K.; Koyama, K.; Machida, Y. Particle characteristics and biodistribution of camptothecin-loaded PLA/(PEG-PPG-PEG) nanoparticles. Drug Delivery 2008, 15 (1), 3-10.
2. Noda, K.; Nishiwaki, Y.; Kawahara, M.; Negoro, S.; Sugiura, T.; Yokoyama, A.; Fukuoka, M.; Mori, K.; Watanabe, K.; Tamura, T.; Yamamoto, S.; Saijo, N; Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 2002, 346 (2), 85-91.
3. Negoro, S.; Masuda, N.; Takada, Y.; CPT-11 Lung Cancer Study Group West. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br. J. Cancer 2003, 88 (3), 335.
4. Bodurka, D. C; Levenback. C; Wolf, J. K. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J. Clin. Oncol. 2003, 21 (2), 291-297.
5. Physician Desk Reference, Camptosar®, 57th ed. Thomson Healthcare, Montvale, N.J, 2003.
6. rd, H. A.; Nelson, J.; Eckardt, J. R.; Tristan-Morales, M.; Hilsenbeck, S. G.; Weiss, G. R.; Smith, L. S.; Rodriguez, G. I.; Rock, M. K.; Von Hoff, D. D. Phase I and pharmacokinetic trial of weekly CPT-11. J. Clin. Oncol. 1993, 11 (11), 2194-2204.
7. Slatter, J. G.; Schaff, L. J.; Sams, J. P. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C] CPT-11 in cancer patients. Drug. Metab. Dispos. 2000, 28 (4), 423-433.
8. Gupta, E.; Lestingi, T. M.; Mick, R.; Ramirez, J.; Vokes, E. E.; Ratain, M. J. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res. 1994, 54 (14), 3723-3725.
9. Koizumi, F.; Kitagawa, M.; Negishi, T.; Onda, T.; Matsumota, S.; Hamaguchi, T.; Matsumura, Y. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res. 2006, 66 (20), 10048-10056.
10. rd ed.; Chabner, B. Á., Longo, D. L., Eds.; Lippincott Williams & Wilkins: Philadelphia, PA, 2001; p 579.
11. Zhang, J. A.; Xuan, T.; Ma, M.; Parmer, L.; Ugwu, S.; Ali, S.; Ahmad, I. Development and characterization of a novel liposome-based formulation of SN-38. Int. J. Pharm. 2004, 270 (1-2), 93-107.
12. Lie, S.; Chien, P. Y.; Sheikh, S.; Zhang, A.; Ali, S.; Ahmad, I. Enhanced therapeutic efficacy of a novel liposome-based formulation of SN-38 against human tumor models in SCID mice. Anticancer Drugs 2004, 15 (8), 773-778.
13. Onishi, Y.; Machida, Y. Antitumor properties of irinotecan-containing nanoparticles prepared using poly (DL-lactic acid) and poly (ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol). Biol. Pharm. Bull. 2003, 26 (1), 116.
14. Esmaeili, F.; Hosseini-Nasr, M.; Rad-Malekshahi, M.; Samadi, N.; Atyabi, F.; Dinarvand, R. Preparation and antibacterial activity evaluation of rifampicin-loaded poly lactide-co-glycolide nano-particles. Nanomedicine: Nanotech. Biol. Medicine 2007, 3 (2), 161-167.
15. Esmaeili, F.; Ghahremani, M. H.; Ostad, S. N.; Atyabi, F.; Seyedabadi, M.; Malekshahi, M. R.; Amini, M.; Dinarvand, R. Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate. J. Drug Targeting 2008, 16 (5), 415-423.
16. Esmaeili, F.; Ghahremani, B.; Esmaeili, B.; Khoshayand, M. R.; Atyabi, F.; Dinarvand, R. PLGA nanoparticles of different surface properties: Preparation and evaluation of their body distribution. Int. J. Pharm. 2008, 349 (1-2), 249-255.
17. Lockman, R.; Mumper, R. J.; Khan, M. A.; Allen, D. D. Nanoparticles technology for drug delivery across the blood-brain barrier. Drug Dev. Ind. Pharm. 2002, 28 (1), 1-13.
18. Grief, R.; Domb, A.; Quellec, P.; Blunk, T.; Müller, R. H.; Verbavatz, J. M.; Langer, R. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv. Drug Del. Rev. 1995, 16 (2-3), 215-233.
19. Cappel, J.; Kreuter, J. Effect of nanoparticles on transdermal drug delivery. J. Microencapsul. 1991, 8 (3), 369-374.
20. Arica, B.; Lamprecht, A. In vitro evaluation of betamethasone-loaded nanoparticles. Drug Del. Ind. Pharm. 2005, 31 (1), 19-24.
21. Pal, A. Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation. Anticancer Res. 2005, 25 (1A), 331-341.
22. Sumitomo, M.; Koizumi, F.; Asano, T.; Horiguchi, A.; Ito, K.; Kakizoe, T.; Hayakawa, M.; Matsumura, Y. Novel SN-38-incorporated polymeric micelle, NK012, strongly suppresses renal cancer progression. Cancer Res. 2008, 68 (6), 1631-1635.
23. Soppimath, K. S.; Aminabhavi, T. M.; Kulkarni, A. R.; Rudzinski, W. E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Controlled Release 70 (1-2), 1-20.
24. Mu, L.; Feng, S. S. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J. Controlled Release 2003, 86 (1), 33-48.
25. Dong, Y.; Feng, S. S. Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials 2004, 25 (14), 2843-2849.
26. Murakami, H.; Kobayashi, M.; Takeuchi, Y.; Kawashima, Y. Preparation of poly (DL-lactide-coglycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. Int. J. Pharm. 1999, 187 (2), 143-152.
27. Niwa, T.; Takeuchi, H.; Hino, T.; Kunou, N.; Kawashima, Y. In vitro drug release behavior of D, L-lactide/glycolide copolymer (PLGA) nanospheres with nafarelin acetate prepared by a novel spontaneous emulsification solvent diffusion method. J. Pharm. Sci. 1994, 83 (5), 727-732.
28. Le Roy Boehm, A. L.; Zerrouk, R.; Fessi, H. Poly epsilon-caprolactone nanoparticles containing a poorly soluble pesticide: Formulation and stability study. J. Microencapsul. 2000, 17 (2), 195-205.
29. Paul, M.; Laatiris, A.; Fessi, H.; Dufeu, B.; Durand, B.; Deniau, M.; Astier, A. Pentamidine-loaded poly(D, L-lactide) nanoparticles: Adsorption and drug release. Drug Dev Res. 1998, 43 (2), 98-104.
30. Holland, S. J.; Tighe, B. J. Biodegradable Polymers. In Advanced Pharmaceutical Science; Garderton, D., Jones, T., Eds; Academic Press: New York, 1992; Vol. 6, p 101.